AMPE - Ampio Pharms's IV Ampion demonstrates safety in COVID-19 study

Ampio Pharmaceuticals ([[AMPE]] +4.3%) has completed its Phase 1 clinical trial and has initiated the first steps for a global Phase 2 clinical trial for intravenous ((IV)) Ampion treatment in COVID-19 patients.Based on data review, the Safety Monitoring Committee found the IV treatment of Ampion to be safe and well-tolerated for 90-days following treatment.The study met its primary safety endpoint after 5 days of IV Ampion treatment and again after 3 months, with no remarkable safety differences between the Ampion treatment and SOC control groups.It also showed promising efficacy with the IV Ampion treatment group seeing stronger clinical improvement than the SOC group as measured by the World Health Organization clinical improvement scale and the National Early Warning Score.Additionally, Ampion-treated patients showed greater improvement compared to patients treated with the SOC, including anti-viral therapies.

For further details see:

Ampio Pharms's IV Ampion demonstrates safety in COVID-19 study